Details

Autor(en) / Beteiligte

• RICART, Elena
• PANACCIONE, Remo
• LOFTUS, Edward V
• TREMAINE, William J
• SANDBORN, William J

Titel

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

Ist Teil von

• The American journal of gastroenterology, 2001-03, Vol.96 (3), p.722-729

Ort / Verlag

Oxford: Blackwell Publishing

Erscheinungsjahr

2001

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this study was to report the clinical outcome and adverse events in the first 100 patients with refractory inflammatory and/or fistulizing Crohn's disease treated with infliximab at the Mayo Clinic. Patient data was abstracted from medical records. Clinical response was classified as complete response, partial response, and nonresponse. Indications for infliximab therapy were: inflammatory disease (61 patients), fistulizing disease (26 patients), or both (13 patients). Patients received one to seven infusions of infliximab (5 mg/kg) for a total of 242 infusions. In all, 50 patients had complete response, 22 had partial response, and 28 had nonresponse. Median time to response was 7 days (range 1-21 days). Median duration of response was 10.3 weeks (range 3-25 wk). A total of 95 patients received concomitant treatment with immune modifiers. Steroid withdrawal was possible in 29/40 patients (73%). Median time of follow-up was 34 wk (range 14-48 wk). Clinically significant adverse events after infliximab included: abscess formation in two patients (perianal, peristomal), pneumonia in two patients, varicella zoster in three patients, candida esophagitis in one patient, and infusion-related reactions in 19 patients. A total of 23 patients were continued on infliximab as maintenance treatment. This study provides additional evidence that infliximab is safe and beneficial in clinical practice for refractory Crohn's disease.